
Oxford BioTherapeutics (OBT) is a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate-based therapies. OBT's IO discovery process provides unique insight into the cancer-immune cell synapse and has identified several novel IO candidates for cancer therapy. Discovery of novel tumour antigens and immune cell surface proteins at OBT is performed using the proprietary Oxford Genome Anatomy Project (OGAP®) database. OBT currently has one ADC in phase 1b clinical trials in collaboration with Menarini. OBT is a dynamic, growing, international biotechnology company based in Oxford, UK, and San Jose, CA.
For further information, please see www.oxfordbiotherapeutics.com
Purpose of the Role
We are seeking a Scientist/Sr/Principal Scientist experienced in ADC and Translational Research to join our team. This person will contribute directly to OBT’s Oncology ADC pipeline and drive innovation with cancer biologists, immunologists, and protein and antibody discovery scientists to develop first-in-class ADC therapies. They must be a team player, strategic thinker, and effective communicator to accomplish the company’s goals in the fast-paced and dynamic industry environment.
The Antibody drug conjugate (ADC) & Translational Science team is at the forefront of developing and delivering novel targeted therapies for the unmet needs to transform the lives of cancer patients. We identify, validate, and advance the discovery of new ADCs through comprehensive biological evaluations of tumor-associated antigens, their targeting antibodies, and linker payloads, as well as vigorous preclinical studies. As we drive toward the next generation of therapeutics, we seek an energetic, highly motivated, and interactively proficient scientist to perform hands-on experiments to advance projects and/or development decisions.
Essential Duties and Responsibilities:
Please note the roles and responsibilities for the position include but are not limited to the above.
Knowledge, Experience, and Skills:
Behaviors:
One of our top priorities is to maintain the health and wellbeing of our employees and their families. To achieve this goal, we offer comprehensive benefits.
Benefits Offered:
Equal Opportunities Statement
OBT is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status, and veteran status. All qualified applicants will receive consideration for employment.
Why Join Us
We promote a culture of innovation, responsibility, and commitment to our goals and objectives. Together, we believe we can pool our resources and our uniqueness to develop novel, robust cures for one of the most challenging health conditions today. We recognize that our team is only as good as the people in it. Our people have used the words friendly, collaborative, and hard working to describe the culture here at OBT. This is why we strive to ensure that we hire only the best people. We also strive to provide a working environment that is based on cooperation, innovation, and mutual respect.
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics.
Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly.
OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe.
The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).
Take the next step in your career journey